Author + information
- Received April 28, 2020
- Revision received May 14, 2020
- Accepted May 20, 2020
- Published online July 15, 2020.
- Sanjum S. Sethi, MD, MPH∗ (, )@sanjum,
- Robert Zilinyi, MD,
- Philip Green, MD,
- Andrew Eisenberger, MD,
- Daniel Brodie, MD,
- Cara Agerstrand, MD,
- Koji Takeda, MD,
- Ajay J. Kirtane, MD, SM,
- Sahil A. Parikh, MD,
- Erika B. Rosenzweig, MD,
- for the CUIMC PERT Team
- ↵∗Address for correspondence:
Dr. Sanjum S. Sethi, Center for Interventional Vascular Therapy, 161 Fort Washington Avenue, Floor 6, New York, New York 10032.
Severe acute respiratory syndrome coronavirus 2 is associated with a prothrombotic state in infected patients. After presenting a case of right ventricular thrombus in a patient with coronavirus disease-2019 (COVID-19), we discuss the unique challenges in the evaluation and treatment of COVID-19 patients, highlighting our COVID-19–modified pulmonary embolism response team algorithm. (Level of Difficulty: Beginner.)
Dr. Sethi has received honoraria from Chiesi, Inc. and Janssen. Dr. Brodie has received research support from ALung Technologies; and has been on the medical advisory boards for ALung Technologies, Baxter, Breethe, Xenios, and Hemovent. Dr. Kirtane has received institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, and ReCor Medical; and has received research grants, institutional funding includes fees paid to Columbia University and/or the Cardiovascular Research Foundation for speaking engagements and/or has received consulting (no speaking/consulting fees were personally received and with travel/meal reimbursements only). Dr. Parikh has received institutional grants/research support from Abbott Vascular, Shockwave Medical, TriReme Medical, and Surmodics; consulting fees from Terumo and Abiomed; and has served on advisory boards for Abbott, Medtronic, Boston Scientific, CSI, Janssen, and Philips. Dr. Rosenzweig has received research funding from Janssen/Actelion, Bayer, Gilead, Lung Rx, and SonVie. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Case Reports author instructions page.
- Received April 28, 2020.
- Revision received May 14, 2020.
- Accepted May 20, 2020.